AR124090A1 - Moduladores del regulador de la conductancia transmembrana de la fibrosis quística - Google Patents
Moduladores del regulador de la conductancia transmembrana de la fibrosis quísticaInfo
- Publication number
- AR124090A1 AR124090A1 ARP210103184A ARP210103184A AR124090A1 AR 124090 A1 AR124090 A1 AR 124090A1 AR P210103184 A ARP210103184 A AR P210103184A AR P210103184 A ARP210103184 A AR P210103184A AR 124090 A1 AR124090 A1 AR 124090A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- optionally substituted
- alkyl
- cycloalkyl
- halogen
- Prior art date
Links
- 201000003883 Cystic fibrosis Diseases 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 20
- 229910052736 halogen Inorganic materials 0.000 abstract 16
- 150000002367 halogens Chemical class 0.000 abstract 16
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 12
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 12
- 150000001875 compounds Chemical class 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000004043 oxo group Chemical group O=* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- -1 -ORX2 and -N(RX2)2) Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115552P | 2020-11-18 | 2020-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124090A1 true AR124090A1 (es) | 2023-02-15 |
Family
ID=79602287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103184A AR124090A1 (es) | 2020-11-18 | 2021-11-18 | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4247817A1 (zh) |
| JP (1) | JP2023549547A (zh) |
| KR (1) | KR20230123522A (zh) |
| CN (1) | CN116670140A (zh) |
| AR (1) | AR124090A1 (zh) |
| AU (1) | AU2021383176A1 (zh) |
| CA (1) | CA3201793A1 (zh) |
| CL (1) | CL2023001398A1 (zh) |
| CO (1) | CO2023007896A2 (zh) |
| CR (1) | CR20230260A (zh) |
| DO (1) | DOP2023000099A (zh) |
| EC (1) | ECSP23045439A (zh) |
| IL (1) | IL302873A (zh) |
| MX (1) | MX2023005721A (zh) |
| PE (1) | PE20231380A1 (zh) |
| WO (1) | WO2022109573A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150237A1 (en) * | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023224931A1 (en) * | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
| WO2024054851A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
| WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
| WO2024056791A1 (en) * | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
| WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103946221B (zh) * | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| PT3752510T (pt) * | 2018-02-15 | 2023-03-15 | Vertex Pharma | Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los |
-
2021
- 2021-11-17 CR CR20230260A patent/CR20230260A/es unknown
- 2021-11-17 CA CA3201793A patent/CA3201793A1/en active Pending
- 2021-11-17 WO PCT/US2021/072475 patent/WO2022109573A1/en active Application Filing
- 2021-11-17 AU AU2021383176A patent/AU2021383176A1/en active Pending
- 2021-11-17 JP JP2023529022A patent/JP2023549547A/ja active Pending
- 2021-11-17 CN CN202180090910.1A patent/CN116670140A/zh active Pending
- 2021-11-17 PE PE2023001653A patent/PE20231380A1/es unknown
- 2021-11-17 MX MX2023005721A patent/MX2023005721A/es unknown
- 2021-11-17 KR KR1020237020002A patent/KR20230123522A/ko unknown
- 2021-11-17 EP EP21843853.9A patent/EP4247817A1/en active Pending
- 2021-11-17 IL IL302873A patent/IL302873A/en unknown
- 2021-11-18 AR ARP210103184A patent/AR124090A1/es unknown
-
2023
- 2023-05-16 CL CL2023001398A patent/CL2023001398A1/es unknown
- 2023-05-17 DO DO2023000099A patent/DOP2023000099A/es unknown
- 2023-06-16 CO CONC2023/0007896A patent/CO2023007896A2/es unknown
- 2023-06-16 EC ECSENADI202345439A patent/ECSP23045439A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000099A (es) | 2023-08-15 |
| MX2023005721A (es) | 2023-07-25 |
| CO2023007896A2 (es) | 2023-09-18 |
| IL302873A (en) | 2023-07-01 |
| KR20230123522A (ko) | 2023-08-23 |
| WO2022109573A1 (en) | 2022-05-27 |
| JP2023549547A (ja) | 2023-11-27 |
| AU2021383176A1 (en) | 2023-06-22 |
| CR20230260A (es) | 2023-10-05 |
| CA3201793A1 (en) | 2022-05-27 |
| ECSP23045439A (es) | 2023-08-31 |
| EP4247817A1 (en) | 2023-09-27 |
| PE20231380A1 (es) | 2023-09-07 |
| CL2023001398A1 (es) | 2023-11-24 |
| CN116670140A (zh) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124090A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| AR123183A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR121044A1 (es) | Inhibidores de egfr | |
| EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| KR950704304A (ko) | 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives) | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| BR9307595A (pt) | Composto, processo para sua preparação, composição herbicida, e, processo para danificar severamente ou exterminar plantas indesejáveis | |
| AR035795A1 (es) | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de la enzima endopeptidasa neutra, uso de los mismos, procedimientos e intermediarios para su preparación y composiciones que contienen dichos inhibidores | |
| AR126073A1 (es) | N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| CO2022003123A2 (es) | Compuestos farmacéuticos | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR062405A1 (es) | Derivados de isoindol | |
| YU4795A (sh) | Derivati indola koji se mogu koristiti kao 5ht agonisti, farmaceutski preparati koji ih sadrže i postupci njihovog dobijanja | |
| AR005338A1 (es) | Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios | |
| AR123962A1 (es) | Inhibidores de interleucina-17 | |
| AR125608A1 (es) | Novedosos compuestos útiles como agonistas de sting y sus usos | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR126733A1 (es) | Inhibidores de nicotinamida ripk1 | |
| AR119378A1 (es) | Formulación de nanopartículas del inhibidor de bcl-2 | |
| PE20211071A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
| AR088202A1 (es) | Inhibidores de la actividad de proteina tirosina quinasa |